Drug Trial Radar · NCT06952010
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
303
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
May 31, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- ExelixisIndustry
- Sponsor type
- Industry
- First posted
- Apr 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
Conditions
- Solid Tumor
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Immune Sensitive Tumor
Interventions
XB628Biological
Intravenous infusion(s)
ZanzalintinibDrug
Oral tablet(s)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Cohort: Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: 21 days
- Dose Escalation Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 27 months
- Dose Expansion Cohort: Objective Response Rate (ORR)Time frame: Up to 27 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Exelixis Clinical Site #5
San Francisco, California · Recruiting
Exelixis Clinical Site #4
New Haven, Connecticut · Recruiting
Exelixis Clinical Site #8
Tampa, Florida · Recruiting
Exelixis Clinical Site #10
Boston, Massachusetts · Recruiting
Exelixis Clinical Site #11
Boston, Massachusetts · Recruiting
Exelixis Clinical Site #6
St Louis, Missouri · Recruiting
Exelixis Clinical Site #7
New York, New York · Recruiting
Exelixis Clinical Site #1
Hickory, North Carolina · Recruiting
Exelixis Clinical Site #3
Nashville, Tennessee · Recruiting
Exelixis Clinical Site #9
Houston, Texas · Recruiting
Exelixis Clinical Site #2
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.